<DOC>
	<DOCNO>NCT02022228</DOCNO>
	<brief_summary>Gonadotropin release hormone ( GnRH ) agonist sufficient trigger final oocyte maturation GnRH antagonist protocol significantly reduce incidence ovarian hyperstimulation syndrome ( OHSS ) high-risk patient . However , low oocyte yield report patient low luteinizing hormone ( LH ) level post trigger single injection GnRH agonist , might relate short duration lower amount LH induce GnRH agonist . Our aim study dual trigger GnRH agonist human chorionic gonadotropin ( hCG ) prevent OHSS maintain clinical outcome high risk patient receive control ovarian stimulation GnRH antagonist protocol .</brief_summary>
	<brief_title>Dual Trigger Reduce Ovarian Hyperstimulation Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>patient polycystic ovarian syndrome patient polycystic ovarian morphology ultrasound patient previously experience ovarian stimulation cycle , high response gonadotrophins patient undergo coast patient past ovarian surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Ovarian Hyperstimulation Syndrome</keyword>
	<keyword>Luteinizing Hormone</keyword>
	<keyword>Polycystic Ovarian Syndrome</keyword>
	<keyword>Ovarian Yield</keyword>
	<keyword>Ovarian Maturity</keyword>
	<keyword>Gonadotropin Releasing Hormone Agonist</keyword>
	<keyword>Human Chorionic Gonadotropin</keyword>
</DOC>